RGEN Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$185.70median target· current $141.01 (+31.7%)22 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
49 articles · sorted by datePage 1 of 3 · 49 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio193.16Forward 68.97
EPS (TTM)$0.73-65.9% YoY
Profit margin5.3%HEALTHCARE
Market cap$7.96BMid cap
Valuation
- Forward P/E
- 68.97
- PEG ratio
- 1.88
- P/B
- 3.77
- P/S (TTM)
- 10.14
- EV/EBITDA
- 45.68
Profitability & growth
- ROE (TTM)
- 2.0%
- Operating margin
- 9.3%
- Revenue growth YoY
- 11.9%
- Dividend yield
- —
- Beta
- 1.06
Last earnings
Jul 28, 2026 · Estimate $0.45 · Reported $0.54
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Repligen Corporation
Company profileRepligen Corporation develops and markets bioprocessing systems and technologies for use in the biologic drug manufacturing process in North America, Europe, Asia Pacific, and internationally. The company is headquartered in Waltham, Massachusetts.
Classification
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- BUILDING 1, WALTHAM, MA
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$7.96B
Shares outstanding$56.4M
52W high$175.77
52W low$100.99
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent